The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
Open accessAbstract
Introduction: The Oncotype DX assay was recently reported to predict risk for distant recurrence among a clinical trial population of tamoxifen-treated patients with lymph node-negative, estrogen receptor (ER)-positive breast cancer. To confirm and extend these findings, we evaluated the performance of this 21-gene assay among node-negative patients from a community hospital setting. Methods: A case-control study was conducted among 4,964 Kaiser Permanente patients diagnosed with node-negative invasive breast cancer from 1985 to 1994 and not treated with adjuvant chemotherapy. Cases (n = 220) were patients who died from breast cancer. Controls (n = 570) were breast cancer patients who were individually matched to cases with respect to age, race, adjuvant tamoxifen, medical facility and diagnosis year, and were alive at the date of death of their matched case. Using an RT-PCR assay, archived tumor tissues were analyzed for expression levels of 16 cancer-related and five reference genes, and a summary risk score (the Recurrence Score) was calculated for each patient. Conditional logistic regression methods were used to estimate the association between risk of breast cancer death and Recurrence Score. Results: After adjusting for tumor size and grade, the Recurrence Score was associated with risk of breast cancer death in ER-positive, tamoxifen-treated and -untreated patients (P = 0.003 and P = 0.03, respectively). At 10 years, the risks for breast cancer death in ER-positive, tamoxifen-treated patients were 2.8% (95% confidence interval [CI] 1.7–3.9%), 10.7% (95% CI 6.3–14.9%), and 15.5% (95% CI 7.6–22.8%) for those in the low, intermediate and high risk Recurrence Score groups, respectively. They were 6.2% (95% CI 4.5–7.9%), 17.8% (95% CI 11.8–23.3%), and 19.9% (95% CI 14.2–25.2%) for ER-positive patients not treated with tamoxifen. In both the tamoxifen-treated and -untreated groups, approximately 50% of patients had low risk Recurrence Score values. Conclusion: In this large, population-based study of lymph node-negative patients not treated with chemotherapy, the Recurrence Score was strongly associated with risk of breast cancer death among ER-positive, tamoxifen-treated and -untreated patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Self-citationELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Statistical methods in cancer research. Volume I - The analysis of case-control studies.
Breslow, N. E., & Day, N. E. (1980) · PubMed · Cited by 4,988
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Self-citationThe analysis of case-control studies
Breslow, N. E., & Day, N. E. (1980) · International Agency for Research on Cancer eBooks · Cited by 2,415
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Rothman, K. J., Greenland, S., & Lash, T. L. (1998) · Cited by 2,096
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Pathological prognostic factors in breast cancer
Elston, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,735
Krieger, N. (1992) · American Journal of Public Health · doi:10.2105/ajph.82.5.703 · Cited by 1,654
Brown, A. S., Brummel‐Smith, K., Burgess, L., D'Agostino, R. B., Goldschmidt, J. W., Halter, J. B., Hazzard, W. R., Jahnigen, D. W., Phelps, C., Raskind, M., et al. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb02362.x · Cited by 1,331
Bear, H. D., Anderson, S., Smith, R. E., Geyer, C. E., Mamounas, E. P., Fisher, B., Brown, A. M., Robidoux, A., Margolese, R., Kahlenberg, M. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1665 · Cited by 943
(2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.979 · Cited by 893
Fritz, W. (1982) · Food / Nahrung · doi:10.1002/food.19820260329 · Cited by 824
Rothman, K. J., Greenland, S., & Lash, T. L. (2008) · Encyclopedia of Quantitative Risk Analysis and Assessment · doi:10.1002/9780470061596.risk0599 · Cited by 706
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Gene expression predictors of breast cancer outcomes
Huang, E., Cheng, S. H., Dressman, H., Pittman, J., Tsou, M. H., Horng, C. F., Bild, A., Iversen, E. S., Liao, M., Chen, C. M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13308-9 · Cited by 627
Gianni, L., Zambetti, M., Clark, K., Baker, J., Cronin, M., Wu, J., Mariani, G., Rodriguez, J., Carcangiu, M., Watson, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0818 · Cited by 626
Self-citationMeeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3817 · Cited by 582
Measurement of Gene Expression in Archival Paraffin-Embedded Tissues
Cronin, M., Pho, M., Dutta, D., Stephans, J. C., Shak, S., Kiefer, M. C., Esteban, J. M., & Baker, J. B. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63093-3 · Cited by 551
Self-citationTrends in Breast Cancer by Race and Ethnicity
Ghafoor, A., Jemal, A., Ward, E., Cokkinides, V., Smith, R., & Thun, M. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.6.342 · Cited by 451
Histological grading of breast carcinomas: A study of interobserver agreement
Robbins, P., Pinder, S., de Klerk, N., Dawkins, H., Harvey, J., Sterrett, G., Ellis, I., & Elston, C. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90010-1 · Cited by 416
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Love, R. R., Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.7.1955 · Cited by 414
Fisher, B., Jeong, J.-H., Bryant, J., Anderson, S., Dignam, J., Fisher, E. R., & Wolmark, N. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16981-x · Cited by 359
Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 300
Fink, A. K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.064 · Cited by 281
Lessons from Controversy: Ovarian Cancer Screening and Serum Proteomics
Ransohoff, D. F. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji054 · Cited by 264
Meyer, J. S., Alvarez, C., Milikowski, C., Olson, N., Russo, I., Russo, J., Glass, A., Zehnbauer, B. A., Lister, K., & Parwaresch, R. (2005) · Modern Pathology · doi:10.1038/modpathol.3800388 · Cited by 262
Pittman, J., Huang, E., Dressman, H., Horng, C.-F., Cheng, S. H., Tsou, M.-H., Chen, C.-M., Bild, A., Iversen, E. S., Huang, A. T., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401736101 · Cited by 222
Gene expression profiling of primary breast carcinomas using arrays of candidate genes
Bertucci, F. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.20.2981 · Cited by 175
Esteva, F. J., Sahin, A. A., Cristofanilli, M., Coombes, K., Lee, S.-J., Baker, J., Cronin, M., Walker, M., Watson, D., Shak, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1707 · Cited by 168
Self-citationAdjuvant Therapy for Breast Cancer: Practice Patterns of Community Physicians
Harlan, L. C., Abrams, J. S., Warren, J. L., Clegg, L., Stevens, J. L., & Ballard-Barbash, R. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.052 · Cited by 119
Estimation of Absolute Risk from Nested Case-Control Data
Langholz, B. M., & Borgan, Ø. (1997) · Biometrics · doi:10.2307/2533977 · Cited by 101
Self-citationThe frequency of kidney and urinary tract diseases in a defined population
Hiatt, R. A., & FRIEDMAN, G. D. (1982) · Kidney International · doi:10.1038/ki.1982.133 · Cited by 75
Some evidence refuting the HMO "favorable selection" hypothesis: the case of Kaiser Permanente.
Gordon, N. P., & Kaplan, G. A. (1991) · PubMed · Cited by 50
Individualized Care for Patients with Cancer — A Work in Progress
Bast, R. C., & Hortobágyi, G. N. (2004) · New England Journal of Medicine · doi:10.1056/nejme048300 · Cited by 48
Long-Term Complications of Adjuvant Chemotherapy for Early Stage Breast Cancer
Partridge, A. H., & Winer, E. P. (2004) · Breast Disease · doi:10.3233/bd-2004-21108 · Cited by 42
Genomic approaches in the management and treatment of breast cancer
Chang, J. C., Hilsenbeck, S. G., & Fuqua, S. A. W. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602410 · Cited by 38
When is a genomic classifier ready for prime time?
Simon, R. M. (2004) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0006 · Cited by 24
Gene expression profiling of primary breast cancer
Rouzier, R., Wagner, P., Morandi, P., & Pusztai, L. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0024-y · Cited by 17
Meyer, J. S., Alvarez, C., Milikowski, C., Olson, N., Russo, I. H., Russo, J., Glass, A. G., Zehnbauer, B. A., Lister, K., & Parwaresch, R. M. (2005) · Modern Pathology · doi:10.1038/modpathol.3800479 · Cited by 13
Cited by
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I.-T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70314-6 · Cited by 1,407
Self-citationGene expression in fixed tissues and outcome in hepatocellular carcinoma
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D. Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M. J., Lerner, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804525 · Cited by 1,286
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Gene expression profiling in breast cancer: classification, prognostication, and prediction
Reis-Filho, J. S., & Pusztai, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61539-0 · Cited by 729
Metadata
- Authors
- Habel, L. A., Shak, S., Jacobs, M. K., Capra, A., Alexander, C., Pho, M., Baker, J., Walker, M., Watson, D., Hackett, J., Blick, N. T., Greenberg, D., Fehrenbacher, L., Langholz, B., & Quesenberry, C. P.
- Venue
- Breast Cancer Research
- Published
- 2006-05-31
- Volume
- 8
- Issue
- 3
- Pages
- R25-R25
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1551461559
- Cited by
- 484
- References
- 49
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.